研究单位：[1]EpimAb Biotherapeutics (Suzhou)Co., Ltd.[2]Peninsula and South Eastern Haematology and Oncology Group,Frankston,Victoria,Australia[3]One Clinical Research,Nedlands,Western Australia,Australia[4]Hunan Cancer Hospital,Changsha,Hunan,China[5]Affiliated Hospital of Hebei University,Baoding,China[6]Cancer Hospital Chinese Academy of Medical Sciences,Beijing,China[7]The First Affiliated Hospital of Bengbu Medical College,Bengbu,China[8]Zhujiang Hospital of Southern Medical University,Guangzhou,China[9]The Affiliated Tumour Hospital of Harbin Medical University,Harbin,China[10]Shandong Cancer Hospital,Shandong,China[11]Tianjin Medical University Cancer Institue & Hospital,Tianjin,China
For solid tumors and lymphoma, respectively: This study is to evaluate the safety and tolerability of EMB-07 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-07 will also be assessed.
